Autopsy report · NCT00723554

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

“sponsor's decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 9 months before it stopped.
• 63 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Actelion

Sponsor type

Industry

Conditions

Pulmonary Arterial Hypertension

Interventions

Iloprost PD-6; Iloprost PD-15

Participants

63

Sites

36

Countries

United States

Trials that died the same way

• Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
  “Sponsor decision” (98% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.